Advances in the application of minimal residual disease in non-metastatic colorectal cancer
10.3760/cma.j.cn441530-20240613-00208
- VernacularTitle:微小残留病灶在非转移性结直肠癌中的应用研究进展
- Author:
Di CAO
1
;
Fang WANG
;
Rongxin ZHANG
;
Bing WEI
;
Mingyan HE
;
Junjie PENG
;
Gong CHEN
Author Information
1. 中山大学肿瘤防治中心结直肠科 华南肿瘤学国家重点实验室 肿瘤医学省部共建协同创新中心，广州 510060
- Keywords:
Colorectal neoplasms;
Circulating tumor DNA;
Minimal residual disease;
Personalized medicine
- From:
Chinese Journal of Gastrointestinal Surgery
2024;27(7):749-755
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, the application of minimal residual disease (MRD) in solid tumors has gained widespread attention. MRD typically refers to the presence of residual cancer cells that remain undetectable by imaging after curative treatments, such as surgical resection. The presence of MRD post-surgery is significantly associated with an increased risk of tumor recurrence. In colorectal cancer, circulating tumor DNA (ctDNA) serves as an effective marker for assessing MRD, particularly in non-metastatic (stages I-III) colorectal cancer. As a real-time, accurate, and convenient biomarker, ctDNA can effectively predict tumor recurrence, guide postoperative adjuvant chemotherapy decisions, and provide crucial information for recurrence monitoring. The application prospects of ctDNA detection technology are vast, promising more precise and individualized treatment plans for colorectal cancer patients. This article comprehensively analyzes the progress in the application of ctDNA for detecting MRD in non-metastatic colorectal cancer patients, elaborates on its guiding role in clinical treatment decisions, and envisions the future development directions in this field.
